where: V = organ wet weight. g, C = concentration, ug g (or ml). t = time. min, Q = flow rate, ml/min, R = tissue-to-plasma equilibrium, distribution ratio, k = clearance, ml/min.
BISCHOFF and co-workers have de- scribed a multicompartment mathematical model for methotrexate (Mtx) pharmacokinetics (Bischoff, Dedrick and Zaharko, 1970 : Bischoff et al., 1971 : Zaharko et al., 1971 : Dedrick, Zaharko and Lutz, 1973 ).
The full model is somewhat complex and is based on a series of mass-balance equations utilizing observed data, initiallH from the mouse, but later extended to other species and to man, and incorporating known flow rates for the organs comprising the compartments. The solution of this set of simultaneous linear differential equations comprises the description of Mtx pharmacokinetics. For example, the mass balance equation for the kidney (see Zaharko et al., 1971) where: V = organ wet weight. g, C = concentration, ug g (or ml). t = time. min, Q = flow rate, ml/min, R = tissue-to-plasma equilibrium, distribution ratio, k = clearance, ml/min.
The subscript K and P refer respectivelv to kidnev and plasma. The model has been used to predict concentrations in tissues in man after intravenous Mtx from the plasma concentration data of Henderson, Adamson and Oliverio (1965) . Since it is an important part of the function of a pharmacokinetic model to predict for data that are important to, but not readily obtainable bv, the clinician using the drug it is essential to determine as far as possible how far the predictions of the model match with subsequently obtained data. We recently studied liver biopsy specimens in 4 patients, 3 at 3 hours and 1 at 24 hours after intravenous [3H] Mtx, and bile from another patient who had a complete biliarv fistula and we were able to compare observed values for hepatic and biliarv Mtx levels with those predicted by the model. The model predicts a liver to plasma ratio of approximately 5: 1 and preferential biliarv excretion of drug.
All patients had inoperable cancer that was not amenable to conventional therapy and were entering a study of the clinical evaluation of Mtx (Selawrv, 1970) ; all gave informed consent to entry into the study. All (Futterman, 1957; Osborn, Freeman and Huennekens, 1958) , an enzyme which is known to have high levels in the liver in animals (Hall, Roberts and Kessel, 1966) . However, levels of this enzyme in human tissues including liver are less than 0-08 nmol Mtx equivalentfIg tissue. Binding to dihvdrofolate reductase could therefore account for less than 10 0 of the total Mtx found at 3 hours and about 5O% of that found at 24 hours. Binding to dihydrofolate reductase cannot therefore account for the high concentrations seen in the liver in the present study.
The preliminary data presented here indicate the need for further human studies to check in man the elaborate pharmacokinetic models derived from animal data, in order to determine how far such models reliablv predict for man.
